Table 5.
|
Screened, % of Survivors |
% Δ Screened vs. Not Screened |
Relative Risk Reduction |
|||||||||
Sev |
Adv |
Mod |
Mild |
Sev |
Adv |
Mod |
Mild |
Sev |
Adv |
Mod |
Mild |
|
Mild VF loss at baseline | ||||||||||||
2 y | 0 | 0 | 15.1 | 84.9 | 0 | 0 | 6 | −6 | N/A | N/A | 0.28 | −0.08 |
5 y | 3.9 | 6.4 | 42.8 | 46.9 | 3.5 | 1.5 | 8.3 | −13.2 | 0.47 | 0.19 | 0.16 | −0.39 |
8 y | 11.7 | 11.3 | 50.2 | 26.8 | 8.1 | 0.5 | 4.3 | −12.9 | 0.41 | 0.04 | 0.08 | −0.93 |
10 y | 13.9 | 10.8 | 52.3 | 23 | 7.6 | −1.4 | 3.8 | −10 | 0.35 | −0.15 | 0.07 | −0.77 |
Moderate VF loss at baseline | ||||||||||||
2 y | 0 | 0 | 100 | 0 | 0 | 0 | 0 | 0 | N/A | N/A | N/A | N/A |
5 y | 11.5 | 21.3 | 67.2 | 0 | 5.2 | 2 | −7.1 | 0 | 0.31 | 0.09 | −0.12 | N/A |
8 y | 22.6 | 29.6 | 47.8 | 0 | 6.9 | 7.4 | −14.3 | 0 | 0.23 | 0.2 | −0.43 | N/A |
10 y | 28.4 | 34.3 | 37.3 | 0 | 7.4 | 6.6 | −14 | 0 | 0.21 | 0.16 | −0.6 | N/A |
Advanced VF loss at baseline | ||||||||||||
2 y | 4.5 | 95.5 | 0 | 0 | 4.2 | −4.2 | 0 | 0 | 0.48 | −0.05 | N/A | N/A |
5 y | 31.3 | 68.7 | 0 | 0 | 7.2 | −7.2 | 0 | 0 | 0.19 | −0.12 | N/A | N/A |
8 y | 45.6 | 54.4 | 0 | 0 | 11.8 | −11.8 | 0 | 0 | 0.21 | −0.28 | N/A | N/A |
10 y | 54.1 | 45.9 | 0 | 0 | 8.9 | −8.9 | 0 | 0 | 0.14 | −0.24 | N/A | N/A |